The generated Trastuzumab-ODN conjugates were tested in vitro to compare their HER2-binding activity, their tumor cytotoxic function and their adjuvanticity to that of unconjugated Trastuzumab and CpG ODN. This evidence concerns the gene ERBB2 and neoplasm.